# Treatment options for primary sclerosing cholangitis
Treatment of PSC aims to slow disease progression, manage symptoms, and prevent complications. Because the underlying cause is not yet fully understood, there is no medication that can stop the disease. The treatments available focus on different aspects: inflammation in the bile ducts, fibrosis (scar tissue), associated intestinal inflammation, and its consequences.
Ursodeoxycholic acid (UDCA)
ProveniIncluded in official guidelines, or approved by EMA or FDA
This bile-derived acid is widely prescribed and works by changing the composition of bile and reducing inflammatory reactions in the bile ducts. It is usually given in the early stage. Studies show that UDCA can help reduce bile stasis (cholestasis) and improve certain liver abnormalities in the blood, although it is unclear whether it stops the ultimate progression to liver failure.
Side effects are generally mild; diarrhea or abdominal cramps occur in a small proportion of patients. UDCA is relatively safe long-term.
Fibrates (fenofibrate, bezafibrate)
ResearchediPositive results in clinical studies, not yet standard treatment
Fibrates are medications that can lower inflammation markers in the blood and improve liver and bile duct function. Positive study results suggest they can slow the progression of fibrosis. Fibrates are not yet recommended as standard treatment in all countries, but research is ongoing into their place in treatment, especially in combination with UDCA.
Known side effects are muscle pain, fatigue, and elevated uric acid levels.
Anti-inflammatory medications targeting bile duct inflammation
ResearchediPositive results in clinical studies, not yet standard treatment
Because PSC is accompanied by persistent inflammation of the bile ducts, medications are being investigated that block specific inflammatory pathways in the body. This aligns with growing insights that immune activation plays an important role.
Studies of medications that target certain signaling proteins (such as FGF receptors) or immune cells aim to reduce fibrosis and inflammation. These are still in investigational stages and are not standard treatment.
Side effects depend on the specific medication; investigational stages will provide more clarity.
Treatment of associated intestinal inflammation (IBD)
ProveniIncluded in official guidelines, or approved by EMA or FDA
Because PSC is often accompanied by inflammatory bowel disease (usually ulcerative colitis), treatment of intestinal inflammation is an important part. Biological medications (for example anti-TNF drugs, integrin inhibitors, and JAK inhibitors) have been used increasingly in recent years and can help control both intestinal inflammation and possibly also the progression of PSC.
Recent data suggest that patients with PSC and IBD who achieve good control of their bowel disease may be better off. This is still being further investigated.
Side effects of biological medications are infections (also from unusual pathogens), skin reactions, and blood cell abnormalities; they require regular monitoring.
Management of bile duct strictures (narrowing)
ProveniIncluded in official guidelines, or approved by EMA or FDA
As PSC progresses, narrowing of the bile ducts develops. These can cause inflammatory conditions, infections, or bile blockage. Endoscopic treatment (ERCP with dilation and stent placement) helps restore bile drainage and is used when symptoms occur or infection risk threatens.
This is not original disease treatment, but a symptomatic procedure. Side effects of the procedure are pancreatitis (pancreatic inflammation) and infections; routine prophylactic antibiotics are sometimes given around procedures.
Treatment of gallbladder polyps and cancer prevention
ProveniIncluded in official guidelines, or approved by EMA or FDA
Patients with PSC have an increased risk of cancer of the bile ducts and adjacent structures. Regular screening with ultrasound and if necessary MRI and blood biomarkers helps detect early changes. Gallbladder removal is sometimes recommended for cancer prevention, especially for polyps above certain sizes.
This is not aimed at slowing disease progression, but at early detection and prevention.
Nutrition and lifestyle measures
ProveniIncluded in official guidelines, or approved by EMA or FDA
Optimal nutrition, weight management and avoiding harmful substances (alcohol, certain supplements) are part of standard care. These measures help keep the liver healthy and prevent complications.
Management of disease symptoms
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many patients with PSC experience fatigue and possibly cognitive impairment (concentration or memory problems). Although no medication targets this, multidisciplinary approaches (activity, sleep, psychological support, treatment of underlying liver disease) may help. This is still in the research phase; studies are looking at which factors can be modified.
Fatigue management requires individual assessment in consultation with the doctor.
Liver fibrosis assessment (non-invasive tests)
ResearchediPositive results in clinical studies, not yet standard treatment
Liver stiffness measurement (elastography) and blood markers (panels of proteins and enzymes) can provide indications of the degree of fibrosis without biopsy and help monitor the disease. Research shows that these tests can better predict progression. They increasingly replace liver biopsy, but are not for treating the disease—they do help with risk prediction.
No side effects.
Liver transplantation
ProveniIncluded in official guidelines, or approved by EMA or FDA
For patients with advanced cirrhosis or liver failure, liver transplantation is the only curative treatment. It is considered when the liver can no longer function adequately despite medication. Transplantation is a major intervention with lifelong immunosuppression, but can provide long-term survival. Recent research examines outcomes in patients with concurrent cancer complications.
Side effects include infections, rejection risk and adverse effects of immunosuppressants.
Experimental and research molecules
ExperimentaliOngoing in study setting, outcome still unknown
Clinical trials are investigating new approaches: agents that block certain receptors (for example FGF receptors), that directly counteract fibrosis, or that target new immune pathways. Artificial intelligence-assisted analysis of liver biopsy also shows promising results for better risk prediction.
These are research interventions in controlled settings. Safety and efficacy can only be confirmed once trials are completed.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._